World Diabetes Drug Market

2011-2021

Product Code VIS00105
Publication Date March 2011
Publisher Visiongain
Product Type Report
Pages 224
ISBN Number not applicable
Change currency
PDF £1,499.00 €1,805 $2,370 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

World Diabetes Drug Market

2011-2021

Where will revenue growth occur in the diabetes treatment market? Our new report shows you the potential that drug market offers from 2011 to 2021, explaining the opportunities there.

Our report gives you revenue forecasts for anti-diabetes agents from 2011 to 2021. We aim to save you time and aid your decisions through our research, data and discussions.

You will discover revenue prospects for diabetes treatments at total world, sub-market, product and national levels. You can stay ahead by ordering our report now.

We show potential revenues for human insulins and analogues, as well as other diabetes treatments. You will discover revenue prospects for Novo Nordisk, GSK, Takeda, sanofi-aventis, Eli Lilly, Merck and other companies from 2011 onwards.

Our report shows you how products like Lantus, Humalog, Novorapid, Novomix, Levemir, Actraphane HM, Actos, Avandia, Avandamet, Januvia and Byetta will perform to 2021.

We also discuss insulin delivery technologies. Our review of research and development includes insulins and analogues, DPP-IV inhibitors, sulfonylureas and alpha-glucosidase inhibitors. You will find out what agents can transform this market.

Our new study discusses how pharma companies can overcome challenges - commercial, regulatory, therapeutic and technological - in the world diabetes treatment market.

We show how companies can seize diabetes market opportunities in developed and developing countries, despite competition, economic uncertainties and pricing concerns.

You can assess the industry's strengths, weaknesses, trends and opportunities from 2011. You will see where diabetes treatment is heading and what companies will do in future.

In our report you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Please respond now to get that information.

Analysis and expert opinion to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 112 tables and charts and two research interviews (shown in the accompanying lists).

We can help you now, making it easier for you to stay ahead in this industry and market.

World Diabetes Drug Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

  • You will receive hard data for the diabetes treatments industry - especially our revenue forecasts to 2021
  • You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where revenue growth will occur
  • You will see revenue prospects for leading products from 2011 to 2021, with discussions of market potential and competition
  • You will find revenue prospects for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China, Russia and India)
  • You will learn how the diabetes treatment industry will change from 2011 to 2021
  • You will assess leading companies providing diabetes treatments, discovering their activities, outlook and revenue prospects
  • You will investigate competition and opportunities influencing the world diabetes drug market from 2011 onwards
  • You will see what will stimulate and restrain the industry and market from 2011
  • You will review diabetes treatment technologies, assessing pharma R&D potential
  • You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed
  • You will analyse opportunities for established companies and those seeking to enter the diabetes drugs market
  • You will view expert opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - distinctive predictions from our work. Our independent analysis helps you to stay ahead in market knowledge for diabetes treatments.

Order our report now to gain industry and market information you need

Our report can benefit everybody interested in diabetes drug development, technology, production, marketing and sales. We give predictions and answers you need. Don't miss out - please order our report now.

Contents

  • 1. Executive Summary
    • 1.1 Trends in the Diabetes Treatment Market: Overview
    • 1.2 Aims, Scope and Format of Report
    • 1.3 Research & Analysis Methods
  • 2. Introduction to Diabetes and its Treatments
    • 2.1 What is Diabetes Mellitus?
    • 2.1.1 Symptoms of Diabetes
    • 2.1.2 Type 1 Diabetes
    • 2.1.3 Type 2 Diabetes
    • 2.1.4 Gestational Diabetes
    • 2.1.5 Other Types of Diabetes
    • 2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic Syndrome
    • 2.2 Health Consequences of Diabetes: Heart, Kidney, Eye and Nerve Damage
    • 2.2.1 Heart Problems
    • 2.2.2 Kidney Damage
    • 2.2.3 Blindness
    • 2.2.4 Neuropathy
    • 2.2.5 Amputation
    • 2.2.6 Ketoacidosis, Coma, and Death
    • 2.3 Obesity: The Major Diabetes Risk Factor
    • 2.4 Other Risk Factors: Age, Genetics and Race
    • 2.4.1 Type 2 Diabetes Risk Increases with Age
    • 2.4.2 Obesity Increases Chances of Type 2 Diabetes
    • 2.4.3 Genetic Factors
    • 2.4.4 Type 1 Diabetes: Genetics versus Environment
    • 2.4.5 Family History
    • 2.4.6 Ethnicity
    • 2.5 Diagnosis: Guidelines are Subject to Change
    • 2.6 Prevalence: Diabetes Levels are Rising
    • 2.7 The Economic Costs of Diabetes
    • 2.8 Treatments
    • 2.8.1 Insulin: A Central Therapeutic Product
    • 2.8.2 Crucial Insulin Characteristics: Onset, Peak, and Duration Modifications
    • 2.8.3 Invasive Insulin Delivery Methods: Injections, Pumps, Insulin Jets
    • 2.8.4 Moving Away from Injections? Delivery Methods under Development
    • 2.8.5 Medications
    • 2.8.6 A New Discovery about How Insulin Works May Lead to New Drugs
    • 2.9 Diabetes Treatment Noncompliance Rates
  • 3. The World Diabetes Drug Market, 2011-2021
    • 3.1 The World Diabetes Drug Market in 2009
    • 3.1.1 Human Insulins and Analogues Held the Largest Market Share in 2009
    • 3.1.2 Top Twenty Anti-Diabetic Drug Brands, 2009
    • 3.2 The World Diabetes Drug Market Forecast, 2011-2021
    • 3.3 Anti-Diabetics Pharmaceutical Therapeutic Category Forecasts, 2011-2021
    • 3.3.1 Two Therapeutic Categories will Drive Growth from 2010-2015
    • 3.3.2 Human Insulins and Analogues will Continue to Drive Growth from 2015 to 2021
    • 3.3.3 Sulphonyl Urea and Biguanide Anti-Diabetics Market - Growth Prospects?
    • 3.3.4 Revenues for Glitazone Anti-Diabetics Will Fall?
    • 3.3.5 Other Therapeutic Classes Will Contribute Significantly
  • 4. Human Insulins and Analogues Market, 2011-2021
    • 4.1 Leading Human Insulins and Analogues
    • 4.1.1 Lantus: Revenue Prospects, 2009-2021
    • 4.1.2 Humalog: Revenue Prospects, 2009-2021
    • 4.1.3 Novorapid: Revenue Prospects, 2009-2021
    • 4.1.4 Novomix: Revenue Prospects, 2009-2021
    • 4.1.5 Levemir: Revenue Prospects, 2009-2021
    • 4.1.6 Actraphane HM: Revenue Prospects, 2009-2021
  • 5. Other Anti-Diabetic Agents: Market Prospects, 2011-2021
    • 5.1 Leading Oral Anti-Diabetic Products
    • 5.2 Glitazone Anti-Diabetics
    • 5.2.1 Actos: Revenue Prospects, 2009-2021
    • 5.2.2 Avandia: Revenue Prospects, 2009-2021
    • 5.2.3 Avandamet: Revenue Prospects, 2009-2021
    • 5.3 DPP-IV Inhibitors
    • 5.3.1 Januvia: Revenue Prospects, 2009-2021
    • 5.3.2 Janumet: Revenue Prospects, 2009-2021
    • 5.4 Byetta/Exenatide LAR: Revenue Prospects, 2009-2021
    • 5.4.1 Byetta's Strengths
    • 5.4.2 Restraints on Byetta
  • 6. Drivers and Restraints in the Diabetes Drug Market
    • 6.1 Strengths: Diabetes Treatments are Effective and the Prevalence of Diabetes is Rising Worldwide
    • 6.1.1 Diabetes is a Chronic Disorder
    • 6.1.2 Younger Patients and More Comprehensive Diagnoses
    • 6.1.3 Prevention Measures Inadequate
    • 6.1.4 Drugs Often Used in Combination
    • 6.2 Weaknesses
    • 6.2.1 Diagnostic Challenges
    • 6.2.2 Insurance Coverage Incomplete, Especially in Developing Countries
    • 6.2.3 High Noncompliance Rates
    • 6.3 Opportunities
    • 6.3.1 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
    • 6.3.2 The Aging of the World Population
    • 6.3.3 Obesity: A Serious Contributing Factor in Type 2 Diabetes
    • 6.3.4 Expanding Markets: India and China
    • 6.3.5 Changing Guidelines for Defining Diabetes
    • 6.3.6 Techniques for Increasing Patient Compliance
    • 6.3.7 Novel Drugs, Novel Delivery Methods
    • 6.4 Threats
    • 6.4.1 Changes in Drug Approval Guidelines
    • 6.4.2 Changing FDA Guidelines for New Drug Approvals
    • 6.4.3 Generic Erosion of Original-Brand Drug Revenues
    • 6.4.4 Vaccine to Prevent Type 1 Diabetes?
    • 6.4.5 Diabetes Drugs: Side Effects
  • 7. Anti-Diabetes Drugs: Leading National Markets, 2011-2021
    • 7.1 Anti-Diabetes Drugs: Leading National Markets, 2009
    • 7.2 Leading Developed Anti-Diabetes Pharmaceutical Market Forecasts, 2011-2021
    • 7.2.1 The US Diabetes Drug Treatment Market
    • 7.2.2 The Japanese Diabetes Drug Treatment Market
    • 7.2.3 Leading European Diabetes Drug Treatment Markets
    • 7.3 Emerging-Economy Anti-Diabetics Pharmaceutical Market Forecasts, 2011-2021
    • 7.3.1 Large Potential Market for Diabetes Treatments in Developing Countries
    • 7.3.2 The Chinese Anti-Diabetics Pharmaceutical Market
    • 7.3.3 The Indian Anti-Diabetics Pharmaceutical Market
    • 7.4 Anti-Diabetic Treatment Revenues in Other National Markets
  • 8. The R&D Pipeline for Diabetes Treatments
    • 8.1 The Anti-Diabetes Drugs R&D Pipeline, 2010-2011
    • 8.2 The Human Insulins and Analogues R&D Pipeline
    • 8.2.1 Technosphere Insulin (MannKind)
    • 8.2.2 VIAject/VIAdel (Biodel)
    • 8.2.3 CKD 401(Chong Kun Dang)
    • 8.2.4 BHT 3021/RG 7426 (Bayhill Therapeutics/Genentech)
    • 8.2.5 Nasulin/CPE-215 (CPEX Pharmaceuticals)
    • 8.2.6 Capsulin (Diabetology)
    • 8.2.7 ORMD 0801 (Oramed)
    • 8.2.8 TPM 02/Insulin (Phosphagenics)
    • 8.2.9 IN 105 (Biocon)
    • 8.2.10 NN 1250 (Novo Nordisk)
    • 8.2.11 NN 5401 (Novo Nordisk)
    • 8.2.12 SBS 1000 (SemBioSys)
    • 8.2.13 LY 2605541 (Boehringer Ingelheim, Eli Lilly)
    • 8.2.14 LY2963016 (Boehringer Ingelheim, Eli Lilly)
    • 8.2.15 NN 1218 (Novo Nordisk)
    • 8.2.16 NN 9068 (Novo Nordisk)
    • 8.2.17 NN 1952 (Novo Nordisk/Merrion)
    • 8.2.18 BIOD620 (Biodel)
    • 8.2.19 DAC: Insulin (ConjuChem)
    • 8.2.20 NODLIN (Biolaxy/NOD Pharmaceuticals)
    • 8.3 The Glitazone Anti-Diabetics R&D Pipeline
    • 8.3.1 ACTOplus XR (Takeda)
    • 8.3.2 Balaglitazone/DRF 2593 (Dr. Reddy's/Nordic Bioscience)
    • 8.3.3 MK 0431C (Merck & Co.)
    • 8.3.4 MSDC 0160 (Metabolic Solutions Development)
    • 8.3.5 Lobeglitazone/CKD 501 (Chong Kun Dang)
    • 8.4 DPP-IV Inhibitor Anti-Diabetics Pipeline
    • 8.4.1 SYR 322 (Takeda)
    • 8.4.2 Alogliptin (Takeda)
    • 8.4.3 Linagliptin/BI 1356 BS (Boehringer Ingelheim)
    • 8.4.4 Dutogliptin/PHX 1149 (Phenomix)
    • 8.4.5 LC 15 0444 (LG Life Sciences)
    • 8.4.6 Saxagliptin + Metformin Combination (AstraZeneca/Bristol-Myers Squibb)
    • 8.4.7 MK 0431C (Merck & Co.)
    • 8.4.8 SK 0403 (Sanwa Kagaku/Kowa/Choongwae)
    • 8.4.9 Teneligliptin/MP 513 (Mitsubishi Tanabe Pharma)
    • 8.4.10 Sitagliptin and Simvastatin (Merck & Co.)
    • 8.4.11 ALS 20426/AMG 222 (Amgen)
    • 8.4.12 Carmegliptin/R 1579 (Roche)
    • 8.4.13 KRP 104 (Kyorin)
    • 8.4.14 Melogliptin/GRC 8200 (Glenmark)
    • 8.4.15 SYR 472 (Takeda)
    • 8.4.16 TA 6666 (Mitsubishi Tanabe Pharma)
    • 8.4.17 DSP 7238 (Dainippon Sumitomo Pharma)
    • 8.4.18 DB160 (DARA/ Nuada)
    • 8.4.19 ARI 2243 (Arisaph/Tufts University)
    • 8.4.20 DA 1229 (Dong-A)
    • 8.5 Sulphonylurea and Biguanide Anti-Diabetics R&D Pipeline
    • 8.5.1 NCT00660907/Dapagliflozin + Metformin Combination (AstraZeneca)
    • 8.5.2 Metformin XL (Flamel Technologies)
    • 8.5.3 Metcontrol (Generex Biotechnology)
    • 8.6 Alpha-Glucosidase Inhibitor Anti-Diabetics R&D Pipeline
    • 8.6.1 KMV 0207 (Kissei/Takeda)
    • 8.6.2 PharmaLinks Compounds (University of Strathclyde)
    • 8.7 Miscellaneous Class of Anti-Diabetic Agents in the R&D Pipeline
    • 8.7.1 Byetta LAR/AC 2993 LAR (Amylin/Alkermes/Eli Lilly)
    • 8.7.2 Albiglutide/GSK 716155 (GlaxoSmithKline)
    • 8.7.3 Lixisenatide/ZP 10/AVE 0010 (sanofi-aventis)
    • 8.7.4 LY 2189265 (Eli Lilly)
    • 8.7.5 Taspoglutide/ BIM 51077 (Roche)
    • 8.7.6 ITCA 650 (Intarcia)
    • 8.7.7 Gosogliptin/PF 734200 (Pfizer)
  • 8 7.8 Semaglutide/NN 9535 (Novo Nordisk)
    • 8.7.9 Bromocriptine/Cycloset (VeroScience/S2 Therapeutics)
    • 8.7.10 SF 1019/R-1818 (Argyll Biotechnologies)
    • 8.7.11 Arhalofenate/MBX 102 (Metabolex and Ortho-McNeil)
    • 8.7.12 Canagliflozin/TA 7284 (Mitsubishi Tanabe Pharma/Johnson & Johnson)
    • 8.7.13 Dapagliflozin (Bristol-Myers Squibb)
    • 8.7.14 DiaPep277 (Andromeda/DeveloGen)
    • 8.7.15 Mirabegron/YM 178 (Astellas)
    • 8.7.16 Otelixizumab/TRX 4/ChAglyCD3 (GlaxoSmithKline/Tolerx/BTG)
    • 8.7.17 Teplizumab/MGA 031 (MacroGenics/Eli Lilly)
    • 8.7.18 DIAMYD/GAD65 (Diamyd Medical)
    • 8.7.19 Dulaglutide (Eli Lilly)
    • 8.7.20 PB1023 (PhaseBio)
    • 8.7.21 HM11260C (Hanmi)
    • 8.7.22 MAR701 (Marcadia)
    • 8.7.23 NN9068 (Novo Nordisk)
    • 8.7.24 NN9924 (Novo Nordisk)
    • 8.7.25 NN9925 (Novo Nordisk)
    • 8.7.26 ORMD0901 (Oramed)
    • 8.7.27 VRS859 (Versartis/Amunix)
    • 8.8 Recent Events in the R&D Pipeline for Anti-Diabetes Treatments
  • 9. Expert Views from Our Survey
    • 9.1 Interview 1: Brand Manager from a Prominent Pharma Company
    • 9.1.1 Views on Current Unmet Needs in the World Diabetes Market
    • 9.1.2 Views on Research and Development for New Anti-Diabetes Products
    • 9.1.3 Views on Growth Opportunities in Current World Markets
    • 9.1.4 Major Threats in the Market
    • 9.2 Interview 2: Dr Vijay Venkatraman Janarthanan, Diabetologist, Pharmacovigilance/Drug Safety Physician and Trainer
    • 9.2.1 Views on the Prevalence of Diabetes
    • 9.2.2 Views on Unmet Market Needs
    • 9.2.3 Views on the Current Pharmacotherapeutic Treatments Available:
    • 9.2.4 Views on Research and Development for Future Anti-Diabetic Treatments
    • 9.2.5 Views on Byetta
    • 9.2.6 Views on Drivers and Restraints in the Market
  • 10. Conclusions
    • 10.1 Diabetes Levels Increasing Worldwide
    • 10.2 The World Diabetes Drug Treatment Market: Many Commercial Opportunities Remain
    • 10.3 Oral Anti-Diabetic Agent Sales versus Insulin Sales
  • List of Tables
    • Table 2.1 World Diabetes Prevalence, 2000 & 2030
    • Table 2.2 Cost of Diabetes in the US, 2007
    • Table 2.3 Cost of Diabetes in Africa, 2008
    • Table 2.4 Types of Insulin, 2010
    • Table 2.5 Delivery Methods in the R&D Pipeline for the Treatment of Diabetes, 2010
    • Table 2.6 Anti-Diabetic Treatments by Therapeutic Class, 2010
    • Table 3.1 World Market Shares (%) & Revenues ($m) of Anti-Diabetic Treatments by Therapeutic Class, 2009, 2015 & 2021
    • Table 3.2 Leading 20 Anti-Diabetic Pharmaceutical Brands: Revenues ($m), 2009
    • Table 3.3 Total Diabetes Pharmaceutical Market Revenues ($m), 2009-2015
    • Table 3.4 Total Diabetes Pharmaceutical Market Revenues ($m), 2015-2021
    • Table 3.5 Anti-Diabetic Pharmaceutical Therapeutic Category Revenues ($m), 2009-2015
    • Table 3.6 Anti-Diabetic Pharmaceutical Therapeutic Category Revenues ($m), 2015-2021
    • Table 4.1 World Lantus Revenues ($m), 2009-2015
    • Table 4.2 World Lantus Revenues ($m), 2015-2021
    • Table 4.3 World Humalog Revenues ($m), 2009-2015
    • Table 4.4 World Humalog Revenues ($m), 2015-2021
    • Table 4.5 World Novorapid Revenues ($m), 2009-2015
    • Table 4.6 World Novorapid Revenues ($m), 2015-2021
    • Table 4.7 World Novomix Revenues ($m), 2009-2015
    • Table 4.8 World Novomix Revenues ($m), 2015-2021
    • Table 4.9 World Levemir Revenues ($m), 2009-2015
    • Table 4.10 World Levemir Revenues ($m), 2015-2021
    • Table 4.11 World Actraphane HM Revenues ($m), 2009-2015
    • Table 4.12 World Actraphane HM Revenues ($m), 2015-2021
    • Table 4.13 World Human Insulins and Analogues Revenues ($m), 2009-2015
    • Table 4.14 World Human Insulins and Analogues Revenues ($m), 2015-2021
    • Table 5.1 World Actos Revenues ($m), 2009-2015
    • Table 5.2 World Actos Revenues ($m), 2015-2021
    • Table 5.3 World Avandia Revenues ($m), 2009-2015
    • Table 5.4 World Avandia Revenues ($m), 2015-2021
    • Table 5.5 World Avandamet Revenues ($m), 2009-2015
    • Table 5.6 World Avandamet Revenues ($m), 2015-2021
    • Table 5.7 World Glitazone Antidiabetics Revenues ($m), 2009-2015
    • Table 5.8 World Glitazone Antidiabetics Revenues ($m), 2015-2021
    • Table 5.9 World Januvia Revenues ($m), 2009-2015
    • Table 5.10 World Januvia Revenues ($m), 2015-2021
    • Table 5.11 World Janumet Revenues ($m), 2009-2015
    • Table 5.12 World Janumet Revenues ($m), 2015-2021
    • Table 5.13 World DPP-IV Inhibitors Revenues ($m), 2009-2015
    • Table 5.14 World DPP-IV Inhibitors Revenues ($m), 2015-2021
    • Table 5.15 World Byetta Revenues ($m), 2009-2015
    • Table 5.16 World Byetta Revenues ($m), 2015-2021
    • Table 5.17 World Total Other Anti-Diabetics Revenues ($m), 2009-2015
    • Table 5.18 World Total Other Anti-Diabetics Revenues ($m), 2015-2021
    • Table 6.1 SWOT Analysis of the World Anti-Diabetes Drugs Market, 2011-2021
    • Table 6.2 Prevalence of Diabetes in Leading National Markets, 2000 & 2030
    • Table 6.3 FDA Guidelines on the Cardiovascular Risk of Diabetes Drugs, 2008
    • Table 7.1 Leading National Markets for Anti-Diabetic Treatments ($m), 2009
    • Table 7.2 US Anti-Diabetic Drug Treatment Revenues ($m), 2009-2015
    • Table 7.3 US Anti-Diabetic Drug Treatment Revenues ($m), 2015-2021
    • Table 7.4 Japanese Anti-Diabetic Drug Treatment Revenues ($m), 2009-2015
    • Table 7.5 Japanese Anti-Diabetic Drug Treatment Revenues ($m), 2015-2021
    • Table 7.6 Top 5 EU Countries: Anti-Diabetic Drug Treatment Revenues ($m), 2009-2015
    • Table 7.7 Top 5 EU Countries: Anti-Diabetic Drug Treatment Revenues ($m), 2015-2021
    • Table 7.8 Leading Emerging Countries: Anti-Diabetes Drug Treatment Revenues ($m), 2009-2015
    • Table 7.9 Leading Emerging Countries: Anti-Diabetes Drug Treatment Revenues ($m), 2015-2021
    • Table 7.10 Rest of the World: Anti-Diabetes Drug Treatment Revenues ($m), 2009-2015
    • Table 7.11 Rest of the World: Anti-Diabetes Drug Treatment Revenues ($m), 2015-2021
    • Table 7.12 National Market Revenues ($m) for Anti-Diabetic Drug Treatments, 2009-2015
    • Table 7.13 National Market Revenues ($m) for Anti-Diabetic Drug Treatments, 2015-2021
    • Table 7.14 National Market Shares (%) for Anti-Diabetic Drug Treatments, 2015 & 2021
    • Table 8.1 Human Insulins and Analogues: Anti-Diabetic Drug Treatments R&D Pipeline, 2010
    • Table 8.2 Human Insulins and Analogues: Anti-Diabetic Drug Treatments R&D Pipeline (continued), 2010
    • Table 8.3 Glitazone Anti-Diabetic Treatments R&D Pipeline, 2010
    • Table 8.4 DPP-IV Inhibitors: Anti-Diabetic Treatments R&D Pipeline, 2010
    • Table 8.5 DPP-IV Inhibitors: Anti-Diabetic Treatments R&D Pipeline (continued), 2010
    • Table 8.6 Sulphonylurea and Biguanides: Anti-Diabetic Treatments R&D Pipeline, 2010
    • Table 8.7 Alphaglucosidase Inhibitors: Anti-Diabetic Treatments R&D Pipeline, 2010
    • Table 8.8 Miscellaneous Class of Anti-Diabetic Treatments: R&D Pipeline, 2010
    • Table 8.9 Miscellaneous Class of Anti-Diabetic Treatments: R&D Pipeline (continued), 2010
    • Table 8.10 Miscellaneous Class of Anti-Diabetic Treatments: R&D Pipeline (continued), 2010
  • List of Figures
    • Figure 2.1 World Diabetes Prevalence, 2000 & 2030
    • Figure 2.2 Cost of Diabetes in the US, 2007
    • Figure 3.1 World Market Shares (%) of Anti-Diabetic Treatments by Therapeutic Class, 2009
    • Figure 3.2 World Market Shares (%) of Anti-Diabetic Treatments by Therapeutic Class, 2015
    • Figure 3.3 World Market Shares (%) of Anti-Diabetic Treatments by Therapeutic Class, 2021
    • Figure 3.4 Total Diabetes Pharmaceutical Market Revenues ($m), 2009-2021
    • Figure 3.5 World DPP-IV Inhibitor Anti-Diabetics Therapeutic Class Revenues ($m), 2009-2015
    • Figure 3.6 World DPP-IV Inhibitor Anti-Diabetics Therapeutic Class Revenues ($m), 2015-2021
    • Figure 3.7 World Human Insulins and Analogues Anti-Diabetics Therapeutic Class Revenues ($m), 2009-2015
    • Figure 3.8 World Human Insulins and Analogues Anti-Diabetics Therapeutic Class Revenues ($m), 2015-2021
    • Figure 3.9 World Sulphonyl Urea & Biguanide Anti-Diabetics Therapeutic Class Revenues ($m), 2009-2015
    • Figure 3.10 World Sulphonyl Urea & Biguanide Anti-Diabetics Therapeutic Class Revenues ($m), 2015-2021
    • Figure 3.11 World Glitazone Anti-Diabetics Therapeutic Class Revenues ($m), 2009-2015
    • Figure 3.12 World Glitazone Anti-Diabetics Therapeutic Class Revenues ($m), 2015-2021
    • Figure 3.13 World Other Anti-Diabetics Therapeutic Class Revenues ($m), 2009-2015
    • Figure 3.14 World Other Anti-Diabetics Therapeutic Class Revenues ($m), 2015-2021
    • Figure 4.1 World Lantus Revenues ($m), 2009-2021
    • Figure 4.2 World Humalog Revenues ($m), 2009-2021
    • Figure 4.3 World Novorapid Revenues ($m), 2009-2021
    • Figure 4.4 World Novomix Revenues ($m), 2009-2021
    • Figure 4.5 World Levemir Revenues ($m), 2009-2021
    • Figure 4.6 World Actraphane HM Revenues ($m), 2009-2021
    • Figure 5.1 World Actos Revenues ($m), 2009-2021
    • Figure 5.2 World Avandia Revenues ($m), 2009-2021
    • Figure 5.3 World Avandamet Revenues ($m), 2009-2021
    • Figure 5.4 World Januvia Revenues ($m), 2009-2021
    • Figure 5.5 World Janumet Revenues ($m), 2009-2021
    • Figure 5.6 World Byetta Revenues ($m), 2009-2021
    • Figure 6.1 Prevalence of Diabetes in Leading National Markets, 2000 & 2030 (Chart 1)
    • Figure 6.2 Prevalence of Diabetes in Leading National Markets, 2000 & 2030 (Chart 2)
    • Figure 6.3 World Population over 65yrs of Age, 2009 & 2025
    • Figure 7.1 National Diabetes Drug Market Shares (%), 2009
    • Figure 7.2 National Diabetes Drug Market Shares (%), 2015
    • Figure 7.3 National Diabetes Drug Market Shares (%), 2021
    • Figure 7.4 US Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.5 Japanese Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.6 US & Japanese Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.7 Top 5 EU Countries: Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.8 Leading Emerging Countries: Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.9 Rest of the World: Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
    • Figure 7.10 Regional Markets: Anti-Diabetic Drug Treatment Revenues ($m), 2009-2021
  • Companies Listed
    • Abbott Laboratories; ActivX; Alkermes; Altea Therapeutics; Alza; American Diabetes Association (ADA); Amgen; Amunix; Amylin Pharmaceuticals; Andromeda Biotech; Argyll Biotechnologies; Arisaph; Astellas Pharma; AstraZeneca; Axcess; Battelle Medical Device Solutions; Baxter International; Bayhill Therapeutics; Biocon; Biodel; Biolaxy; Boehringer Ingelheim; Bristol-Myers Squibb; BTG; Center for Biotechnology and Genomic Medicine, Medical College of Georgia, US; Chiesi; Chinese State Food and Drug Administration (SFDA); Chong Kun Dang Pharmaceutical; Choongwae Pharma; Chugai; College of Pharmacy, Washington State University, WA, US; ConjuChem; CPEX Pharmaceuticals; DARA; DeveloGen; Diabetology; Diamyd Medical; Dainippon Sumitomo Pharma; Dong A; DPT Dong Sung Industrial; Dr. Reddy's Laboratories; Eli Lilly; Emisphere Technologies; Ergo Sciences; European Medicines Agency (EMEA/EMA); European Patent Convention; Flamel Technologies; Food and Drug Administration (FDA) [US]; Forest Laboratories; Galenix Pharma; Garvan Institute of Medical Research, Sydney, Australia; Genentech; Generex Biotechnology; GlaxoSmithKline (GSK); Glenmark Pharmaceuticals; Hanmi; Human Genome Sciences; Immunosyn; Indiana University (US); Intarcia Therapeutics; International Diabetes Federation (IDF); Ipsen; Janssen Pharmaceuticals; Johnson & Johnson; Juvenile Diabetes Research Foundation (US); Kissei Pharmaceutical; Kowa Company.; KYORIN Pharmaceutical Co.; LG Life Sciences; Lifescan UK (Ortho Clinical Diagnostics); MacroGenics; MannKind; Marcadia; Merck & Co.; Merrion; Metabolex; Metabolic Solutions Development; Mitsubishi Tanabe Pharma; NOD Pharmaceuticals; Nordic Bioscience; Novartis; Novo Nordisk; Nuada; Ono; Oramed; Ortho-McNeil; PDL BioPharma; Pfizer; PharmaLinks; PhaseBio; Phenomix; Phosphagenics; Proxima Concepts; Qdose; Roche; Royal Adelaide Hospital, Adelaide, Australia; S2 Therapeutics; Sanford Children's Health Research Center, La Jolla, California, US; sanofi-aventis; Sanwa Kagaku Kenkyusho; SemBioSys Genetics; Servier Laboratories; Takeda Pharmaceuticals; Teijin Pharma Limited; Teva Pharmaceutical Industries; The National Diabetes Information Clearinghouse; Tolerance Therapeutics; Tolerx; Tufts University; University of California at Los Angeles (UCLA), US; University of Strathclyde, Glasgow, UK; VeroScience; Versartis; Washington State University, WA, US; Watson Pharmaceuticals; World Diabetes Congress of the International Diabetic Federation; World Health Organization (WHO); Yeda Research and Development Company; Ypsomed Holding; Zealand Pharma